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Abstract
Malaria is a potentially fatal blood disease spread by mosquitos. Malaria is
preventable, but it is more prevalent in developing countries where prevention is
difficult and prophylaxis is often inaccessible. Malaria remains one of the world’s
most serious public health problems, according to the World Health Organisation
(WHO). The development of resistance is a current problem that poses a danger to
the environment. Resistance is a current problem that could jeopardise the use of
well-established and cost-effective antimalarials. The World Health Organisation
recommends an artemisinin-based drug combination (ACT) to avoid or postpone
the development of resistance. This book’s chapter discusses current medicines as
well as potential and rational possibilities for finding new drugs to treat malady.
There were also WHO recommendations for both complicated and non-
complicated malaria. Other preventive measures such as ITN and IPT are listed in
the manuscript in addition to routine care. While a brief overview of the vaccine
tested so far has been included, there is currently no vaccine available to treat
malaria.
Keywords: Malaria, Plasmodium falciparum, artemisinin, drug repurposing, drug
resistant malaria
1. Introduction
Malaria is a life-threatening disease spread by mosquito bites from infected
female Anopheles mosquitos (“malaria vectors”). The Plasmodium parasite is borne
by infected mosquitos. When an individual is bitten by this mosquito, the parasite is
released into the bloodstream. Malaria is caused by a parasitic protozoan of the
genus Plasmodium. Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and
Plasmodium falciparum are the four types of malaria parasites that can infect
humans. Plasmodium falciparum and Plasmodium vivax are the two most deadly
species, responsible for more than 95 percent of all malaria cases worldwide. Each
year, approximately 125 million pregnant women are at risk of infection; maternal
malaria is linked to up to 200,000 reported child deaths in Sub-Saharan Africa.
[1, 2] Maternal malaria is often linked to a number of negative outcomes for the
mother, the foetus, and the infant.
The sporozoite form of the protozoan is preserved in the salivary glands of the
mosquito. When a person is bitten by an infected female Anopheles mosquito,
sporozoites are injected into the bloodstream and easily move into the human liver.
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The sporozoites replicate asexually in the liver cells for the next 7 to 10 days,
causing no symptoms. The parasites are released in the form of merozoites from the
liver cells and settle in the capillaries of the lungs. Merozoites are released from lung
capillaries in the blood phase (also known as pathologic blood stages) of their
growth, invading red blood cells (erythrocytes) and multiplying until the cells
burst. This cycle continues forever, invading younger red blood cells. These infec-
tions in the blood can last for months. Some infected blood cells break the asexual
multiplication cycle. Merozoites evolve into sexual forms of the parasite called
gametocytes (precursors of male and female gametes) in these cells, which then
circulate in the bloodstream. Malaria parasites will now abandon their human hosts
and complete their life cycle in an insect vector. When a fertilised mosquito bites an
infected individual, the gametocytes in the blood are swallowed by the mosquito,
and the gametocytes mature in the mosquito gut. An ookinete is a fertilised, motile
zygote produced when male and female gametocytes fuse. Ookinetes grow into new
sporozoites, which migrate to the salivary glands of the bug, ready to infect a new
host and restart the human infection cycle (Figure 1) [3].
Only certain species of mosquitoes of the Anopheles genus—and only females of
those species—can transmit malaria. Chills, high fever, profuse sweating, headache,
muscle pains, malaise, diarrhoea, and vomiting are all common symptoms of
malaria. Malaria, on the other hand, is marked by occasional paroxysmal febrile
episodes (i.e., a sudden recurrence or intensification of fever), and untreated infec-
tion results in spleen enlargement. P. falciparum can affect the lungs, liver, and
kidneys, as well as cause extreme anaemia and coma in cerebral malaria, which
sometimes leads to death. P. malariae infection can cause kidney damage, which can
lead to nephrotic syndrome, which can be fatal. Malaria infections are highly
debilitating and can render a person vulnerable to other diseases [4].
Figure 1.
Malaria parasite life cycle; outlines the steps of the parasite as it is injected into the human victim.
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2. Prevention
The primary method for preventing and reducing malaria transmission is vector
control. All people at risk of malaria should be covered with successful malaria
vector control, according to theWHO. Insecticide-treated mosquito nets and indoor
residual spraying are two types of vector control that are effective in a variety of
situations [1].
2.1 Insecticide-treated mosquito nets
An insecticide-treated net (ITN) is a mosquito-blocking bed net that has
been treated with a protected, residual insecticide for the purpose of killing and/or
repelling mosquitoes. By providing both a physical barrier and an insecticidal
effect, sleeping under an ITN may minimise mosquito-human interaction.
Nets treated with insecticide have been shown to minimise infant mortality.
Uncomplicated P. falciparum and P. vixax malaria episodes are also reduced by
ITN [1, 2].
2.2 Indoor residual spraying (IRS)
Indoor residual spraying (IRS) consists of spraying a residual insecticide on the
walls and other housing structures once or twice a year [1]. Mosquitoes and other
insects that come into contact with these surfaces can be destroyed by the insecti-
cide. Several pesticides have been used for IRS in the past, with DDT being the first
and most well-known. Pyrethroids are also used in IRS, where they are sprayed on
indoor surfaces.
3. Vaccines against malaria
Since there is currently no effective way to eradicate malaria, developing safe,
effective, and cost-effective vaccines against the disease remains a top priority. The
malaria vaccine RTS,S/AS01E (RTS,S; (brand name MosquirixTM) is the first and
only vaccine to demonstrate that it can substantially reduce malaria in young
African children, including life-threatening extreme malaria. RTS,S/AS01E is a
candidate for a pre-erythrocytic P. falciparum vaccine. Over a four-year period, the
vaccine prevented approximately 4 in 10 cases of malaria among children who
received four doses in large-scale clinical trials [3]. A vaccine targeting the whole
body, a live attenuated vaccine, a genetically modified vaccine, and a subunit
vaccine are among the four alternatives to a malaria vaccine that have been studied.
Preclinical and clinical studies have recently revealed that Pf sporozoite (SPZ)
vaccines show great promise for human safety, but larger sample sizes are required
to confirm their protective effects [3, 4].
4. Treatment
Malaria must be identified quickly in order to minimise infection spread in
the population and avoid deaths. Before beginning care, the WHO suggests
that all reported cases of malaria be confirmed using microscopy or a rapid
diagnostic test.
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4.1 Antimalarial drugs
Malaria-endemic areas are visited by an estimated 50 million tourists per year.
Chemoprophylaxis, which suppresses the blood stage of malaria infections, may be
used to avoid malaria in such travellers. WHO recommends at least three doses of
sulfadoxine-pyrimethamin intermittent preventive treatment for pregnant women,
particularly those living in moderate-to-high transmission areas. Similarly, for
infants living in high-transmission areas of Africa, three doses of sulfadoxine-
pyrimethamine intermittent preventive care are recommended. Seasonal malaria
chemoprevention has been advised by theWorld Health Organisation (WHO) since
2012. It entails giving all children under the age of 5 months monthly courses of
amodiaquine plus sulfadoxine-pyrimethamine [5].
5. Cinchona alkaloids
The medicinal use of the bark of the cinchona tree, which is native to South
America, is the starting point for the discovery and synthesis of quinine and syn-
thetic quinoline-containing antimalarial drugs. The quinoline derivatives quinine,
quinidine, cinchonidine, and cinchonine are the four most abundant biologically
active alkaloids found in the bark (Figure 2). The bark also includes quinoline
derivatives such as quinicine (also known as quinotoxine) and indole-containing
alkaloids including cinchonamine [6].
.
5.1 Quinine and quinidine
Quinine is the first example of a pure chemotherapeutic agent to be produced on
an industrial scale and it was the only drug available for the treatment of malaria
Figure 2.
Structures of the four major and two minor quinoline containing alkaloids obtained from the bark of the
cinchona tree.
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until the 1930s. Quinine has been used for “fevers” in South America since the
1600s. It is one of the major alkaloids was first used to treat malaria as early as the
beginning of the 17th century, and became the standard therapy for malaria from
the mid-19th century to the 1940s. The extraction of QN is still more economically
viable than its synthetic production [6]. The pure alkaloids, quinine, and cinchonine
were isolated in 1820. The stereoisomer, quinidine, is a more potent antimalarial,
but it is also more toxic (less selectively toxic). Quinine is lethal for all Plasmodium
schizonts and the gametocites from P. vivax and P. malariae, but not for P.
falciparum. Today, quinine’s spectrum of activity is considered too narrow for
prophylactic use relative to the synthetic agents [7].
The emergence of resistant strains of P. falciparum was first reported in the
1980s [8] and as of 2006, quinine is no longer used as a front-line treatment for
malaria but is still on the WHO’s Model List of Essential Medicines (MLEM) [9] for
the treatment of severe malaria in cases where artemisinins are not available. The
mechanism of resistance to quinine is poorly understood and varies with the sus-
ceptibility of the parasite to other aminoquinoline antimalarial drugs. Quinine is the
only treatment recommended for pregnant women in the first trimester3 and, until
recently, it was the only clinical option for the treatment of severe malaria because
it can be formulated for safe intravenous administration. However, intravenous
artesunate is now preferred when available [10].
QN in clinical uses most often combined with a second agent to shorten the
duration of therapy and thus minimise the adverse effects [11]. A toxic syndrome is
referred to as cinchonism. Symptoms start with tinnitus, headache, nausea, and
disturbed vision. If administration is not stopped, cinchonism can proceed to
involvement of the gastrointestinal tract, nervous and cardiovascular system, and
the skin. The stereoisomer, quinidine, is a schizonticide, but its primary indication
is cardiac arrhythmias. It is a good example where stereochemistry is important
because it provides a significantly different pharmacological spectrum [12].
6. 4-Aminoquinolines
4-aminoquinolines (4-AQ), 4-anilinoquinolines, 9-aminoacridines, and
azaacridines are all members of this class. These groups are thought to have similar
mechanisms of action, are successful on the same stage of the parasite, and may
share similar mechanisms of resistance, in addition to their structural similarity
(Figures 3 and 4).
4-Aminoquinoline is a type of aminoquinoline in which the amino group is
located at the quinoline’s 4-position. Antimalarial agents derived from
4-aminoquinoline can be used to treat erythrocytic plasmodial infections.
Amodiaquine, chloroquine, and hydroxychloroquine are some examples [13].
Malaria is treated with 4-aminoquinolines (4-AQs) during the blood stage of the
disease (the merozoites). The unprotonated form of these drugs is a weak base that
can cross the food vacuolar membrane of parasites; however, once within the
vacuole, both the quinoline nitrogen and the amino group of the side chain of 4-AQs
become protonated species that is impermeable to the vacuolar membrane, causing
ion-trapping inside the vacuole [14].
6.1 Chloroquine and hydroxychloroquine
Chloroquine, a 4-aminoquinoline, prevents ferriprotoporphyrin IX polymerisa-
tion, causing oxidative membrane damage and parasite death in infected erythro-
cytes. Because of widespread resistance, it’s normally only used to treat malaria
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Figure 3.
General chemical structure of 4-aminoquinoline.
Figure 4.
Structures of some representative 4-aminoquinolines.
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patients in situations where chloroquine susceptibility can be guaranteed. Malaria
caused by P. falciparum is almost always immune to choloroquine, with the
exception of cases acquired in Haiti.
Chloroquine is only effective against the parasite’s erythrocytic stages; for the
full cure of P. vivax and P. ovale infections, another agent (primaquine) is needed.
Chloroquine has been used in conjunction with dehydroemetine to treat invasive
amebiasis that has not responded to other treatments and to treat connective tissue
autoimmune disorders that have not responded to other treatments.
Chloroquine is thought to get stuck in the parasite’s food vacuole, where it
prevents -hematin from crystallising. The acidic nature of the vacuole (pH 4.8–5.2)
causes chloroquine to become ‘trapped’ in its membrane-impermeable doubly
protonated shape, which is membrane-impermeable. Chloroquine then forms a
complex with free heme, causing heme to accumulate and the parasite to die. P.
falciparum resistant strains were discovered to have a mutation in the Pfcrt gene,
which encodes the chloroquine resistance transporter (Pfcrt) protein [8, 9]. Because
of changes in the membrane protein, this transporter protein induces reduced drug
concentration inside the food vacuole, allowing chloroquine to disperse away from
the vacuole. CQ-resistant parasite strains have a neutral threonine residue at posi-
tion 76 of the Pfcrt protein in place of the positively charged lysine moiety, allowing
chloroquine efflux from the digestive vacuole [15–17].
Within the parasite’s food vacuole, the parasite catabolises the protein of the
host cell haemoglobin, resulting in peptides, which are further degraded to produce
amino acids, which are used by the parasite for survival and development. As a
byproduct of haemoglobin degradation, free heme (iron (II) centred porphyrin) is
produced, which quickly oxidises to hematin (iron (III) centred species). Heme and
hematin are also extremely toxic to parasites. Heme may interfere with the para-
site’s organelles’ various membranous structures, causing irreversible damage and
disrupting transport processes and ion homeostasis. Multiple pathways result in
parasite death. 25.19 Biomineralisation removes heme and hematin, resulting in
hemozoin, a parasite-unfriendly substance. Hloroquine prevents or inhibits the
parasite’s ability to detoxify heme, resulting in parasite death [18–20].
Chloroquine tablets are bitter in taste and are available in the United States.
Chloroquine suspensions are commonly available for paediatric use in other coun-
tries and are much more well tolerated. As a malaria chemoprophylactic, chloro-
quine may be used. Most people tolerate chloroquine well, even when used for long
periods of time. Mild gastrointestinal symptoms (which are usually relieved if the
medication is taken with food), intermittent headaches, blurred vision, dizziness,
weakness, confusion, hair depigmentation, skin eruptions, corneal opacity, weight
loss, and myalgias are all potential side effects. Antihistamines are commonly used
to treat intense pruritus, which is a common problem among black Africans who
take the medication. Patients with psoriasis, retinal disease, or porphyria should
avoid chloroquine. In most respects, hydroxychloroquine is similar to chloroquine.
The only structural difference is a hydroxy moiety on one of the N-ethyl groups. It
stays in the body for over a month, much like chloroquine, and prophylactic dosing
is once weekly. Children tolerate hydroxychloroquine better [21–24].
6.2 Amodiaquine
Amodiaquine was first documented to have antimalarial activity in 1946,
but due to its toxicity, it was removed as a prescribed monotherapy in the early
1990s. It acts in a similar way to chloroquine and has some cross-resistance with
CQ, but it does not have any advantages over other 4-aminoquinoline drugs [25]
(Figure 5).
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It had a higher rate of extreme hepatitis and agranulocytosis than chloroquine
when used for malaria prophylaxis. The toxicity of amodiaquine is thought to be
due to P450-mediated and/or autooxidation of the 1, 4-aminophenol group, which
produces a quinone imine intermediate [26] (Figure 6).
Amodiaquine’s efficacy against some chloroquine-resistant Plasmodium
falciparum strains has led to a resurgence in its use, especially in combination
therapy with artesunate. Although amodiaquine resistance in some parts of Africa
can restrict the effectiveness of this combination in those areas, the artesunate–
amodiaquine combination has proven to be very effective in areas where
amodiaquine alone produces responses of more than 80% [27].
6.3 Mefloquine
The racemic form of mefloquine is the newest of the 4-aminoquinolines. The
drug’s optical isomers are all active in the same way. The US Army [28] built it in
the 1970s. It was initially developed to treat chloroquine-resistant malaria, but it has
since been used as a curative and prophylactic medication (travellers coming into
regions of malaria) (Figure 7).
Mefloquine differs from other 4-aminoquinoline agents in that it has two
trifluromethyl moieties at positions 2 and 8, and no electronegative substituents at
positions 6 (quinine) or 7 (mefloquine) (chloroquine). Mefloquine is not
schizonticidal, which distinguishes it from chloroquine and its analogues. Meflo-
quine is slowly metabolised to carboxymefloquine, its main inactive metabolite,
through CYP3A4 oxidation. The majority of the parent compound is excreted in its
natural state in the urine [29] (Figure 8).
Figure 5.
The inter-nitrogen distance in the side chains of amodiaquine and CQ.
Figure 6.
Metabolic activation of amodiaquine to amodiaquine iminoquinone.
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P. falciparum mefloquine-resistant strains were first identified in 1986 [23]. In
rats, rodents, and rabbits, mefloquine causes teratogenicity. This medication comes
with an FDA-mandated warning that it can worsen mental illnesses, and the neu-
ropsychiatric effects can be severe (e.g., suicidal impulses or seizures) or mild (e.g.,
headaches) (e.g., dizziness, vertigo, ataxia, and headaches). Bradycardia, arrhyth-
mias, and extrasystoles are all possible cardiovascular side effects [30].
7. 8-Aminoquinolines
Another big class of antimalarial drugs based on the cinchona alkaloid quinoline
moiety is substituted 8-aminoquinolines (Figure 9). The 8-aminoquinolines were
the first synthetic antimalarial drugs approved by the FDA. The German
researchers introduced pamaquine as the first compound in this sequence. Due to its
high toxicity and restricted activity, pamaquine was no longer used in clinical trials
[31]. In 1950, primaquine was introduced as a pamaquine analogue. It was the only
approved treatment for removing the Plasmodium parasite from the liver and
preventing malaria relapses caused by P. ovale and P. vivax until July 2018 [32].
Figure 8.
Metabolic activation of mefloquine to carboxymefloquine.
Figure 7.
Racemic forms (RS & SR) of mefloquine.
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In patients with erythrocytic glucose-6-phosphate dehydrogenase deficiency, all
of the 8-aminoquinolines have been reported to cause hemolytic anaemia. This is a
common genetic trait in people who live in malaria-endemic areas [33]. Since 4-AQs
are active during the blood stages of the parasite life cycle, and the blood stages of P.
falciparum can be cultured and thus studied relatively easily, the mechanism of
action for 8-aminoquinolines (8-AQs) is less well known than for
4-aminoquinolines (4-AQs) [34, 35].
The mechanism of action for the 8-AQs cannot be inhibition of hemozoin for-
mation because liver cells do not produce haemoglobin. Primaquine suggested an
autoxidation of the 8-amino group to produce ROS. Augusto et al. [36] suggested
the creation of a radical anion at the 8-amino group. Cell-destructive oxidants like
hydrogen peroxide, superoxide, and the hydroxyl radical can form as a result,
causing oxidative damage to essential cellular components.
The structure–activity relationships in this series display very little variance.
The four agents in Figure 9, all have the same 6-methoxy moiety as quinine, but
the substituent on quinoline are at position 8 rather than carbon-4, as they are
on cinchona alkaloids. Between the two nitrogens, all of the agents in this
sequence have a four to five carbon alkyl linkage or bridge. The other three
8-aminoquinolines, with the exception of pentaquine, all have one asymmetric
carbon. Although there are some variations in the metabolism of each stereoisomer
and the form of adverse reaction, there are little differences in antimalarial activity
based on the stereochemistry of the compounds. In patients with a glucose-6-phos-
phate dehydrogenase deficiency, all of the 8-aminoquinolines can cause hemolytic
anaemia (G6PD). This is a common genetic trait found in people who live in
malaria-prone areas. The key clinical problems associated with primaquine are a
short half-life (4–6 hours), which means it must be taken everyday for 14 days to be
successful, and hemolysis [37–40].
7.1 Primaquine
Primaquine (PQ), an 8-aminoquinoline that has been clinically used since 1950,
is still the only drug used worldwide to treat relapsing P. vivax malaria caused by
Figure 9.
Structures of some representative 8-aminoquinolines.
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hypnozoites, and it inhibits gametocyte formation. It is not used in the prevention
of disease. The only drug available for treating P. vivax and P. ovale latent hepatic
life cycle forms is primaquine [41, 42]. Following the initiation of chloroquine
treatment for the erythrocytic stages of infection, primaquine is recommended for
the radical cure of these infections. It has one of the narrowest spectrums of activity
of any currently used antimalarial drug, as it is only indicated for exoerythrocytic P.
vivaxmalaria. Chloroquine or a drug prescribed for chloroquine-resistant P. vivax is
combined with primaquine to treat endoerythrocytic P. vivax. It is also active
against the exoerythrocytic stages of P. ovale and the main exoerythrocytic stages of
P. falciparum [43], in addition to its accepted indication.
Primaquine is readily absorbed, widely spread, and cleared mainly by non-renal
removal. Carboxyprimaquine is the primary metabolite. Primaquine is successful
when administered once daily or even once weekly [44], despite the fact that the
medication is quickly removed from the plasma. Except in people with G6PD
deficiency, where administration can cause brisk hemolysis, primaquine is typically
well tolerated. Prior to starting primaquine therapy, patients should be tested for
G6PD deficiency. Regardless of G6PD status, primaquine should never be given to a
pregnant woman. Neutropenia, gastrointestinal disturbances, and methemoglobi-
nemia are rare side effects. P. vivax relapses after primaquine therapy have been
treated with chloroquine and higher doses or longer courses of primaquine [45].
Primaquine is the most effective currently available prophylactic for P. vivax
malaria and equivalent to such regimens as doxycycline, mefloquine, and
atovaquone-proguanil for the prevention of P. falciparum malaria, according to a
recent meta-analysis and systematic review [46, 47]. NPC1161B, a chiral 8-
aminoquinoline derivative developed at the University of Mississippi, was still
undergoing preclinical testing in 2014 [48–52].
8. Artemisinin and its derivatives
Artemisinin (ART), a sesquiterpene lactone1, was discovered in 1971 by Tu
Youyou, a Chinese scientist, in the plant Artemisia annua (a herbaceous plant in the
Asteraceae family), which is widely used in Chinese traditional medicine [55].
Youyou shared the Nobel Prize in Physiology or Medicine in 2015 for “her findings
concerning a novel therapy against malaria” [56], owing to the significant positive
effect of ART in the fight against malaria.
Artemisinins are successful not only against multi-resistant strains of Plasmo-
dium falciparum, but they also have strong stage specificity against the Plasmodium
life cycle, including activity during the asexual blood stages [57] as well as the
sexual gametocyte stages, which may help to minimise disease spread in low-
transmission areas [58]. Artemisinin resistance was first recorded in western Cam-
bodia in 2008 [59]. ART and its derivatives have been used as first-line drugs in the
treatment of malaria since their antimalarial activity was discovered.
Since chemical synthesis of ART is considered to be costly, the key commercial
sources of ART are field-grown leaves and flowering tops of A. annua. Since mature
plants will lack the active drug, the plant must be grown from seed every year. To
1 Sesquiterpene lactones (SLs) are a type of sesquiterpene with a lactone ring; a sesquiterpene has three
isoprene (2-methyl-1,3-butadiene) units. Lactones are cyclic carboxylic esters with a 1-oxacycloalkan-2-
one structure (C(=O)O); sesquiterpene lactones (SLs) are present primarily in Asteraceae plants (daisies,
asters). Umbelliferae (celery, parsley, carrots) and Magnoliaceae (magnolias) are two other plant
families with SLs [53, 54].
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maximise artemisinin yield, the increasing conditions must be perfect. Plants grown
in North Vietnam, China’s Chongqing province, and Tanzania have recorded the
highest yields so far [60].
As compared to other compounds historically and currently used, the
artemisinin sequence is structurally distinct. The endoperoxide (C–O–O–C) and
dioxepin oxygens tend to form a “trioxane,” which appears to be the most signifi-
cant structural element. Artemisinine, a sesquiterpene trioxane lactone with an
endoperoxide bridge that is necessary for antimalarial activity, does indeed repre-
sent a new chemical class of antimalarial agents. It distinguishes artemisinins from
other antimalarial drugs by limiting cross-resistance. Artemisinin derivatives such
as artemether, artesunate, and arteether are the most common. These semi-
synthetic derivatives are prodrugs that are converted to dihydroartemisinin, the
active metabolite. Unlike quinine, artemisinin derivatives destroy young circulating
parasites until they sequester in the deep microvasculature [61–65] (Figure 10).
Following oral administration, the artemisinins are rapidly absorbed, with
maximum plasma concentrations occurring in 2 to 3 hours for artemisinin and
artemether, and less than 1 hour for artesunate [66, 67]. Artemisinin is transformed
to inactive metabolites in the liver, such as deoxyartemisinin, deoxydihydroar-
temisinin, and others, where the endoperoxide group is lost and the metabolites
become ineffective. CYP2B6 is the enzyme that catalyses the reaction. Different
artemisinin derivatives are metabolised. They’re converted to dihydroartemisinin
first (DHA). DHA is a potent antimalarial molecule that lasts for two to three hours
in the bloodstream. Artesunate’s antimalarial operation is mediated exclusively by
DHA. (Direct antimalarials include artemisinin, arteether, artemether, and others.)
Within a minute of absorption, artesunate is converted to DHA. DHA is converted
to inactive metabolites in the liver by the cytochrome P450 enzyme system (which
includes CYP2A6, CYP3A4, and CYP3A5). Both metabolites are glucuronidated
before being excreted in the urine or faeces. Artemisinins are relatively safe drugs
due to their quick metabolism [68–70].
Artesunate is a water-soluble semisynthetic form of artemisinin that can be
taken orally or injected intravenously or intramuscularly. Artesunate is superior to
artemisinin and other oil-based derivatives [71] due to its chemical property and
pharmacokinetic profile, as it is almost instantly converted into dihydroartemisinin
after ingestion, which accounts for the antimalarial activity. The endoperoxide
pharmacophore alone has stimulated the production of many different groups of
totally synthetic endoperoxides, including the trioxolane OZ277 [72] and the
tetraoxane 3 [73], despite the fact that the exact mechanism of action is still highly
debated [72] (Figure 11).
Although the exact mechanism of artemisinin is unknown, it is thought to be
triggered by haem, which produces free radicals, which damage parasite survival
proteins [74, 75]. The initial formation of highly reactive oxygen-centered radicals
Figure 10.
Structural units of artemisinine family of compounds.
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by iron(II)-catalysed homolytic cleavage of the peroxide bond is thought to result in
rapid intramolecular rearrangement to give cytotoxic carbon-centered radical
organisms, which then cause widespread damage to parasite biomolecules by
alkylation or by initiating peroxidation (Figure 12).
9. Polycyclic antimalarial drugs
Three antimalarial drugs have polycyclic ring structures in common (Figure 13).
Doxycycline, a popular tetracycline antibiotic, is the first. The second is
halofantrine, and the third is quinacrine [76], a discontinued agent that was used in
the South Pacific.
9.1 Halofantrine
The Walter Reed Army Institute of Research [77] developed halofantrine in the
1960s and 1970s. It is a phenanthrene-type compound that is structurally distinct
from all other antimalarial drugs. The trifluromethyl moiety [78] is an excellent
example of drug design that integrates bioisosteric concepts. Halofantrine is a
synthetic antimalarial that functions as a blood schizonticide but has no effect on
Figure 11.
Pharmacophoric structures of ART derivatives.
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the sporozoite, gametocyte, or hepatic stages of the parasite. It works against
P. falciparum malaria that is immune to several drugs (including mefloquine).
The mechanism of action of halfantrine against the parasite is unknown. It tends
to prevent heme molecules from polymerising (by the parasite enzyme “heme
polymerase”), allowing the parasite to become infected by its own waste. CYP3A4
converts halofantrine to N-desbutyl-halofantrine, which is excreted primarily in the
Figure 12.
Structures of ART derivatives.
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faeces; both the parent compound and the N-desbutyl metabolite are involved
in vitro.
Halofantrine is usually well tolerated, but consistent absorption requires that it
be taken with a fatty meal. Halofantrine has been shown to block open and
inactivated HERG channels preferentially, disrupting nerve conduction in cardiac
tissue and inducing cardiotoxicity. Cardiac arrhythmias are the most dangerous side
effect: halofantrine induces severe QT prolongation [79], which is seen even at
normal doses.
9.2 Doxycycline
Doxycycline is a tetracycline derived from oxytetracycline that inhibits patho-
gen protein synthesis by reversibly inhibiting the 30S ribosomal subunit, preventing
the 50s and 30s units from bonding. Since the ribosomal subunits of bacteria and
Plasmodium differ significantly from mammalian ribosomes, this class of
antibiotics does not readily bind to mammalian ribosomes and therefore has good
selective toxicity [80].
Antimalarial doxycycline is mainly used for prophylaxis against P. falciparum
strains immune to chloroquine and sulfadoxine–pyrimethamine. During malaria
exposure, 100 mg (adult dose) of doxycycline should be given every day as pro-
phylactic therapy. It can also be used in conjunction with quinine to treat resistant
P. falciparum infections, although it has a slow onset of action in acute malaria and
should not be used alone [81]. When treating acute cases, 100 mg of doxycycline
per day for seven days should be given in accordance with quinine.
Doxycycline is well absorbed when taken orally (90–100% when fasting;
decreased by 20% when taken with food or milk) and excreted partially in the
faeces and partially in the urine. Since tetracyclines chelate calcium, they can
Figure 13.
Structures of some representative polycyclic antimalarial compounds.
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interfere with the growth of permanent teeth in children. Doxycycline should only
be used in children for a limited period. Tetracycline also increased photosensitiv-
ity, which is important because areas where malaria is endemic also have the most
sunlight [82].
9.3 Pyronaridine
Pyronaridine was developed in 1970 at the Institute of Chinese Parasitic Disease
[83, 84], and has been used in clinical trials in China since the 1980s. It is one of the
components of the artemisinin combination therapy pyronaridine/artesunate and
has been shown to be effective against chloroquine-resistant strains (Pyramax). It’s
also being investigated as a possible anticancer medication and Ebola treatment.
Pyonaridine, like lumefantrine, tends to interfere with haematin, but it does not
seem to share resistance mechanisms with chloroquine [85]. Pyronaridine is a form
of pyronaridine that is The most common side effects of pyronaridine are headache,
vomiting, stomach pain, bradycardia, and hypoglycemia.
9.4 Lumefantrine
Lumefantrine was first synthesised in China in 1976 and is now only used in
conjunction with artemether. This mixture is often referred to as a “co-artemether”
[86]. Lumefantrine is very lipophilic and has a much longer half-life than
artemether, so it’s thought to remove any lingering parasites after a combined
injection. [No. 29] Lumefantrine has an uncertain molecular weight, but studies
indicate that it inhibits the development of -hematin by forming a complex with
hemin [87].
9.5 Quinacrine
Quinacrine (also known as mepacrine) was commonly used as a prophylactic
during WWII, and was marketed under the brand name Atabrine [88]. Quinacrine
is a derivative of methylene blue, a different anti-malarial discovered in 1891
[89, 90]. Quinacrine is no longer used because it has a high risk of harmful side
effects, such as toxic psychosis [88]. It is one of the most dangerous antimalarial
medications, despite the fact that it was once widely used (Table 1).
Intercalation of DNA strands, succinic dehydrogenase and mitochondrial elec-
tron transport, and cholinesterase are all sites where it functions within the cell. It





Completed Phase II trials in 2017 (NCT02851108) as a
combination with primaquine
Fosmidomycin Antibiotic Phase II trials in 2015 (NCT02198807) as a combination
with piperaquine
Rosiglitazone Antidiabetic drug In clinical trials as an adjunctive therapy for severe malaria
(NCT02694874)
Imatinib In cancer treatment In Phase II trials (NCT03697668) as a triple combination
with dihydroartemisinin-piperaquine
Sevuparin In treatment of sickle
cell disease
Last in Phase I/II trials in 2014 (NCT01442168) as a
combination with atovaquone-proguanil.
Table 1.
List of drugs repurposed in malaria treatment.
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has been used as a sclerosing agent and may be tumorgenic and mutagenic.
Quinacrine can cause yellow discoloration of the skin and urine because it is an
acridine dye.
10. Fixed combinations
Resistance is a common concern in malaria prophylaxis and treatment; combi-
nation therapy seeks to minimise resistance through synergism and, when com-
bined with longer-acting medications, improved therapy. Combination therapies
have been developed that employ two distinct mechanisms.
10.1 Sulfadoxine and pyrimethamine
A sulfonamide antibacterial drug and a pyrimidinediamine similar to trimetho-
prim are used in this combination. Sulfonamides can be used in conjunction with
pyrimethamine in a variety of ways. A sulfonamide with similar pharmacokinetic
properties to the dihydrofolate reductase inhibitor is usually used (Figure 14).
Sulfadoxine, a sulfonamide with a structure identical to p-aminobenzoic acid
(PABA), inhibits the parasite’s ability to synthesise folic acid, whereas pyrimeth-
amine, a pyrimidinediamine, prevents folic acid from being reduced to its active
tetrahydrofolate coenzyme type. Sulfonamides avoid the production of
dihydropteroic acid by preventing the incorporation of p-aminobenzoic acid
(PABA). Since humans do not need to synthesise folic acid, sulfonamides have
excellent selective toxicity. Nonetheless, sulfadoxine has been linked to serious to
fatal cases of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal
necrolysis, and serum sickness syndromes. Pyrimethamine, first formulated in the
1950s, prevents the conversion of folic acid and dihydrofolic acid to the active
tetrahydrofolate coenzyme form, which is required for amino acid and nucleic acid
synthesis [91]. This combination is recommended for the prevention and treatment
of P. falciparum chloroquine resistance and can be used in conjunction with quinine.
Despite the fact that the combination is only suggested for P. falciparum, it is
successful against all asexual erythocytic forms. It does not have any impact on the
sexual gametocyte form [92].
10.2 Atovaquone and proguanil
Two separate and unrelated mechanisms of action against the parasite serve as
the foundation for this combination. Atovaquone is a dihydrofolate reductase
inhibitor, and cycloguanil is a selective inhibitor of the Plasmodium mitochondrial
electron transport system. In a ratio of 2.5 atovaquone to 1 proguanil HCl calculated
Figure 14.
Chemical structure of pyrimethamine and sulfadoxine in combination.
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in mg (not mmoles), atovaquone and proguanil are given together [93]. The sporo-
zoite stage is the primary focus of this mixture. Proguanil decreases the effective
concentration of atovaquone needed to damage the mitochondrial membrane, while
atovaquone increases the effectiveness of proguanil but not its active metabolite
(Malarone) (Figure 15) [94–96].
Atovaquone was first formulated as an antimalarial, however due to its high
failure rate (30%), it is no longer prescribed as a single chemical entity. However,
atovaquone has been combined with proquanil to produce an effective prophylactic
and therapeutic antimalarial [98]. Proguanil is an early example of a prodrug,
having been produced in 1945. CYP2C19 is the enzyme that converts it to
cycloguanil (Figure 16).
The chemistry of atovaquone is based on the fact that it is a naphthoquinone that
participates in oxidation–reduction reactions as part of its quinonehydroquinone
mechanism. The drug targets mitochondrial electron transport, specifically at the
cytochrome bc1 site of the parasite. This deprives the cell of required ATP, poten-
tially contributing to anaerobic conditions. A mutation in the parasite’s cytochrome
causes resistance to this drug, and a single-point mutation appears to be adequate
[99]. The pharmacokinetics of atovaquone, when used as a monotherapy, are
thought to be related to resistance. Since atovaquone is lipophilic and has a slow
absorption rate, the pathogen is exposed to low concentrations of the medication for
a prolonged period of time, which promotes resistance growth.
Cycloguanil (Proguanil) inhibits dihydrofolate reductase, which prevents
deoxythymidylate synthesis. Amino acid shifts near the dihydrofolate reductase
binding site are linked to resistance to proguanil/cycloguanil. Malaria immune to
chloroquine, halofantrine, mefloquine, and amodiaquine is treated with this
drug combination. To date, there has been no evidence of resistance to the
combination [100].
Figure 15.
Chemical structure of atovaquone and proguanil in combination. Sulfadoxine–pyrimethamine are among the
other reportedly used combinations [97].
Figure 16.
Metabolic activation of proguanil to cycloguanil.
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10.3 Artemether and lumefantrine
Artemether–lumefantrine (Coartem) is one of the artemisinin-based combina-
tion therapy’s fixed-dose formulations (ACT). The cure rates for these ACTs have
been stated to be greater than 90%. Artesunate–fosmidomycin, amodiaquine–
artesunate, chloroquine–artemisinin, and artesunate.
Artemether–lumefantrine interferes with heme metabolism, preventing devel-
opment of parasite in erythrocyte states. Artemether acts oxidatively due to its
endoperoxide, and lumefantrine can form a complex with hemin (Figure 17).
11. Future prospects of antimalarial drugs
With the recent emergence of resistance to existing frontline artemisinin-based
combination therapy, the antimalarial drug pipeline is in dire need of newer lead
molecules. The need for new anti-malarials that function through novel mecha-
nisms of action has been moved to the forefront of the development agenda
(Figure 18).
A variety of criteria are used to determine the ability of newer compounds to
function as new anti-malarials: single-dose cures (artesunate and chloroquine are
unable to do this); activity against both the asexual blood stages that trigger disease
and the gametocytes that transmit the disease; compounds that avoid infection
(chemoprotective agents); and compounds that clear P. vivax hypnozoites from the
liver (anti-relapse agents) [101, 102].
Researchers can experiment with new combinations and formulations of
currently available anti-malarial drugs. This may aid in the delivery of the drug,
allowing it to be more successful, or it may help resolve issues with resistance to a
specific component. The following are some recent methods used in the detection of
new antimalarial agents:
1.Use of available antimalarial drugs to improve antimalarial therapy
2.Development of analogs of currently available medications.
3.Covalent bitherapy
Figure 17.
Chemical structure of artemether and lumefantrine in combination.
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4.Exploitation of natural products and their derivatives.
5.Use of compounds that are effective against other diseases
6.Development of compounds that are active against novel targets.
7.Drug resistance reversers
8.Development of a malaria vaccine
11.1 Optimization of antimalarial therapy with available drugs
This technique involves mixing existing medications with new dosing regimens
or formulations, as well as optimising treatment with currently available drugs.
Other non-artemisinin-based combination therapies, in addition to the already
proven and recommended artemisinin-based combination therapy, are intended to
prevent the development of resistance, improve effectiveness, and tolerability. The
idea is to combine two or more drugs with different mechanisms of action, resulting
in different molecular targets in the parasite. In an area where P. falciparum trans-
mission is endemic and Chloroquine resistance is high, chloroquine combined with
sulfadoxine-pyrimethamine demonstrated a large therapeutic return over
sulfadoxine-pyrimethamine alone.
11.2 Development of analogs of available drugs
This technique includes altering existing compounds chemically in order to
produce newer compounds that are more potent, stronger, and cost-effective. The
benefit of this strategy is that the biological target or mechanism of action of the
lead compound is already known. Chemical modifications of quinine, for example,
led to the discovery of chloroquine, halofantrine, and primaquine.
Figure 18.
Structures of some drugs repurposed for malaria therapy and are under various phases of clinical trials.
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11.3 Covalent bitherapy
Covalent bitherapy entails the covalent bonding of two chemical moieties that
act on different/same biological targets through different mechanisms of action
[103–105]. Trioxaquine (SAR116242) is a synthetic hybrid compound with 1,2,4-
trioxane and 4-aminoquinoline pharmacophores covalently related [106–108].
Since covalently linked pharmacophore is designed to target the parasite by:
alkylation of heme with the trioxane moiety and binding of heme with the
aminoquinoline moiety to inhibit hemozoin formation [109, 110], trioxaquine has
been found to work on both asexual and sexual stages of malaria parasites.
11.4 Exploitation of natural products and their derivatives
Natural ingredients have long been a mainstay in drug production. The study of
natural products, mostly by reverse pharmacology, yields useful knowledge about
molecular models for the creation of new drugs. Natural molecular scaffolds
including quinine, artemisinin, febrifugine, spiroindolone, and lapachol, for
example, were discovered in herbal medicinal products [111].
11.5 Exploitation of compounds active against other diseases
This technique, also known as drug repurposing, could be used to combat
malaria. Existing medicines that were previously used for other purposes could be
found to be effective against malaria and repurposed as a new anti-malarial medi-
cation. N. M. Pazhayam et al. [112] looked at a variety of FDA-approved drugs that
could be repurposed as antimalarials.
11.6 Development of compounds active against novel targets
The sixth strategy is the most clinically tested and appealing modern chemo-
therapy strategy. It requires knowledge of genomics and proteomics methods that
have the potential to speed up the detection of new drug targets and the subsequent
discovery of molecules that function on these targets. The identification and char-
acterisation of putative targets in a particular biochemical pathway for parasite
growth is an urgent need to combat the disease, given the rapid emergence of drug
resistance to traditional therapeutics. Our fast advancement in the characterisation
of the genomes of malaria parasites suggests that this strategy is plausible to identify
important new antimalarial compounds in the future. Because of our rapid progress
in sequencing the genomes of malaria parasites, we conclude that this approach will
be useful in discovering essential new antimalarial compounds in the future.
11.7 Drug resistance reversers
The discovery and production of drug resistance reversers not only revitalises
the use of chloroquine and other antimalarial drugs, but also offers a new way to
keep existing drugs effective [113]. For example calcium channel blockers [114] like
verapamil and diltiazem have been shown to reverse chloroquine resistance.
11.8 Development of a malaria vaccine
Vaccination of infectious diseases has a long history of success in curing disease.
Similarly, malaria vaccination is being introduced to protect the vaccinated indi-
vidual while also preventing malaria transmission in the environment. Malaria
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vaccines can prove to be a dynamic approach to malaria control and eradication.
Malaria vaccines target three stages of the parasite’s life cycle: (i) pre-erythrocytic
(sporozoite/hepatic), (ii) erythrocytic (asexual), and (iii) reproductive
(transmission blocking).
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